IL-18 blockade is a potential disease-modifying therapy for rheumatoid arthritis

Christine Plater-Zyberk,Lab Joosten,Mma Helsen,P Sattonnet-Roche,C. Siegfried,Sami Alouani,Faj van de Loo,Pierre Graber,Shuki Aloni,Charles A. Dinarello,W.B. van den Berg,Yolande Chvatchko

IL-18 blockade is a potential disease-modifying therapy for rheumatoid arthritis

2001

Christine Plater-Zyberk
Lab Joosten
Mma Helsen
P Sattonnet-Roche
C. Siegfried
Sami Alouani
Faj van de Loo
Pierre Graber
Shuki Aloni
Charles A. Dinarello
W.B. van den Berg
Yolande Chvatchko

Interleukin-18 (IL-18) has been demonstrated as promoting the development of a TH1 response in vivo in synergy with IL-12. Significant levels of IL-18 and IL-12 have been detected in the joints of patients with rheumatoid arthritis (RA).

Keywords:

Destructive Arthritis
Immunology
Diabetes mellitus
Rheumatology
Rheumatoid arthritis
Disease
Cartilage oligomeric matrix protein
In vivo
Blockade
Medicine
Internal medicine
Interleukin 18

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations